CareDx Shares Latest Clinical Data at the TTS 2020 Virtual Conference
Ashraf Dada , MD, KingFaisal Hospital ,Jeddah – AlloSeq dd-cfDNA and Risk Prediction in Kidney TransplantationStan Jordan , MD, Cedars Sinai – Clinical Utility of Non-invasive Molecular Biomarkers: Understanding Molecular Injury- Shiang-Cheng Kung, MD, UCSF – Clinical Utility of AlloSure
Jonathan Bromberg , MD,University of Maryland – AlloSure: A Guide to Understanding Molecular Injury in Transplant Allografts- Georg Bohmig, MD,
Medical University ofVienna – AlloSeq dd-cfDNA: Donor-derived Cell-free DNA for Organ Injury Detection Luciano Potena , MD,University of Bologna – dd-cfDNA as a Biomarker for Subclinical Acute Rejection in Heart Allograft Transplantation
Nicolae Leca , MD,University of Washington – Resolution by AlloSure Differentiates Ambiguous RejectionSanjiv Anand , MD,Intermountain Medical Center – Relative Change Value of AlloSure: Guidance for Clinical CareKeith Melancon , MD,George Washington University – The GW Clinical Experience: AlloSure Surveillance in Kidney Transplant PatientsNicole Ali , MD,NYU Langone Health - SARS-CoV-2 & Renal Transplantation: The NYU Langone Experience- Arjang Djamali, MD,
University of Wisconsin – AlloSure Case Studies from theUniversity of Wisconsin
- Suphamai Bunnapradist, MD,
UCLA – Relative Change Value of AlloSure: the DART Experience Sudhir Thaduri , MD,University of Alabama at Birmingham – Immunosurveillance with AlloSure Plus Donor Specific Antibody, an Alternative to Renal Allograft BiopsyDhiren Kumar , MD,VCU Health – Resolution by AlloSure Differentiates Ambiguous RejectionNicole Ali ,MD NYU Langone Health – SARS-CoV-2 & Renal Transplantation: the NYU Langone ExperienceMatthew Cooper , MD, Georgetown MedStar – AlloSure Case Studies fromMedStar Georgetown Hospital
Additionally, there are six posters on
Jonathan Bromberg , MD,University of Maryland – Characterization of an Integrative Prognostic Score for US Patients Taken from the DART StudyEugene DePasquale , MD,Keck School of Medicine ,USC – dd-cfDNA as a Risk Factor for Initiating De-novo Donor Specific Antibodies in Heart TransplantationStan Jordan , MD, Cedars Sinai – The Use of dd-cfDNA as a Predictive Tool for Future Proteinuria- Oyedolamu Olaitan, MD,
Rush University – Use of dd-cfDNA as a Surrogate Marker of Injury Following Hypothermic Machine Profusion Anthony Langone , MD,Vanderbilt University – Value of dd-cfDNA when Considering Recipient Ethnicity to Further Help Risk Stratify Transplant Recipients- Markus Wharmann, MD,
Medical University ofVienna – Detection of donor-derived cell-free DNA: Non-invasive Prediction of Silent Antibody-mediated Rejection in Donor-specific Antibody-positive Renal Allograft Recipients
“It is critical to provide a continued education platform for the transplant community in this new virtual world. I am glad that
“We look forward to presenting significant data at TTS this year and are taking a very active role in this important congress,” said
About CareDx
CONTACTS:
Chief Marketing Officer
415-287-2393
sking@caredx.com
Investor Relations
646-924-1769
investor@caredx.com
Source: CareDx, Inc.